Specify a stock or a cryptocurrency in the search bar to get a summary
Codexis Inc
0I0XCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California. Address: 200 Penobscot Drive, Redwood City, CA, United States, 94063
Analytics
WallStreet Target Price
6.86 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 0I0X
Dividend Analytics 0I0X
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0I0X
Stock Valuation 0I0X
Financials 0I0X
Results | 2019 | Dynamics |